Neurobell
NeuroBell Ltd. is an Irish medical device spin-out from University College Cork developing NeuroBell Luna, a portable AI-powered EEG monitor with automated neonatal seizure detection for use in hospital NICUs, currently in clinical validation ahead of regulatory clearance.
- Company typePrivate
- Founded2023
- HeadquartersCork, Ireland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Neurobell does
NeuroBell Ltd. is an Irish medical device company developing NeuroBell Luna, a portable, pocket-sized, wireless EEG monitor with built-in AI-powered automated seizure detection intended for use in neonatal intensive care units (NICUs). The device is an 8-channel, battery-powered, WiFi-enabled system with an ACNS-compliant montage and 10-20 EEG placement for neonates, featuring a simplified two-button setup so non-specialist NICU staff can deploy it. A cloud-connected review and storage layer supports remote interpretation by clinicians. The product addresses a clinical need in which neonatal seizures — a common manifestation of newborn brain injury — frequently have no visible physical signs and currently require specialist neurological monitoring that is often unavailable, causing delays in diagnosis and treatment.
The underlying technology combines custom hardware (the portable EEG monitor), proprietary deep learning software for automated seizure detection, and clinically-annotated EEG datasets accumulated since 2015 at the INFANT Research Centre, University College Cork. NeuroBell's IP is patent-pending, and the company operates an ISO 13485-certified quality management system for medical device design, development, and manufacturing. Founded as a UCC spin-out in 2023, NeuroBell is currently in clinical validation with hospital partners in Ireland (Cork University Hospital) and the United States (Parkview Health, Texas Children's Hospital), working toward FDA clearance and a US market launch targeted for 2026, with European commercialization expected to follow.
Commercially, NeuroBell plans a hardware-led, direct enterprise sales model to hospital NICUs following regulatory approval; pricing has not been publicly disclosed and no commercial sales have yet begun. The company is funded by a €2.1 million seed round closed in November 2023, co-led by Furthr VC and Atlantic Bridge with participation from the HBAN MedTech Syndicate and Enterprise Ireland, alongside earlier support from an Enterprise Ireland Commercialisation Fund. The team currently comprises 6 leadership members plus engineers across firmware, software, data science, and QA, with a stated plan to grow to 12 employees by 2025 ahead of its first commercial launch.
Neurobell firmographics
Firmographics- Name
- Neurobell
- Legal name
- NeuroBell Ltd.
- Website
- https://neurobell.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NeuroBell Ltd. is an Irish medical device spin-out from University College Cork developing NeuroBell Luna, a portable AI-powered EEG monitor with automated neonatal seizure detection for use in hospital NICUs, currently in clinical validation ahead of regulatory clearance.
- Ownership category
- akta.pro rank
Neurobell industry classification
Industry- Product category
- Neonatal EEG Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industries
- Maternal, Neonatal & Pediatric Remote Monitoring (HLACAPAG), Maternal & Neonatal Remote Monitoring Platforms (HLACAFAC)
Keywords
Where Neurobell is headquartered
LocationHeadquarters
- HQ city
- Cork
- HQ country
- Ireland
- HQ region
- Europe
Offices1 record
Markets served
Neurobell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Medical Device Sales (Luna): Sale of NeuroBell Luna, a portable EEG monitoring device with AI-powered seizure detection for neonatal ICUs. Product is currently undergoing clinical validation prior to regulatory submissions and is not yet commercially available in EU or US.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Neurobell product offering
Product offeringCore offering
NeuroBell develops Luna, a portable, pocket-sized, wireless 8-channel EEG monitor with AI-powered automated seizure detection for use in neonatal ICUs. The device is battery-powered, WiFi-enabled, compliant with ACNS and 10-20 EEG placement for neonates, and features a two-button setup process for NICU staff. It integrates deep-learning automated seizure detection with cloud-based EEG data review and storage, providing bedside decision support.
Product overview
Neurobell offers a single unified product, NeuroBell Luna, which is a portable brain monitoring device designed specifically for neonatal seizure detection. The device combines hardware (pocket-sized wireless EEG monitor) with AI-powered software (automated seizure detection via machine learning) and cloud connectivity for data review and storage. The product is currently undergoing clinical validation prior to regulatory submissions and is not yet available for commercial sale in the EU or US.
Differentiator
Problem solved
Functional benefit
Brands
- NeuroBell Luna: Portable brain monitor with AI-powered seizure detection for neonatal ICUs
Products and services
- NeuroBell Luna A portable, pocket-sized, wireless 8-channel EEG monitor with AI-powered automated seizure detection for use in neonatal intensive care units. Battery-powered and WiFi-enabled, with ACNS-compliant 10-20 EEG placement, a two-button user-friendly setup process for NICU staff, and cloud-based review and storage of EEG data for bedside decision support.
Quantifiable outcome
- 1 in 200 newborns suffer brain injury; seizures are most common manifestation requiring treatment
- +1 more outcomes
Companies that use Neurobell
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles1 record
Neurobell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Neurobell partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- INFANT Research Centre, UCCcoreNeuroBell was spun out from University College Cork's internationally-renowned INFANT Research Centre. Technology and IP developed through research at this centre since 2015.
- Cork University Hospital (CUH)coreClinical validation partner for NeuroBell Luna development in EU.
- Parkview HealthcoreUS clinical validation partner for NeuroBell Luna. Partnership established June 2023.
- Texas Children's HospitalcoreUS clinical validation partner for NeuroBell Luna development.
- University College CorkcoreNeuroBell is a spin-out from UCC. The university provides ongoing research collaboration and support through the INFANT Research Centre.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Neurobell competitors and assessment
Company assessmentDirect peers
- Ceribell: Ceribell develops AI-powered point-of-care EEG systems for seizure detection in hospital settings. It is the most direct comparable to NeuroBell Luna, sharing the AI/portable/cloud strategy and targeting rapid bedside brain monitoring without requiring neurophysiologists.
- Compumedics: Compumedics manufactures clinical EEG equipment and AI-supported sleep/neurology diagnostics. It is comparable to NeuroBell's EEG hardware-and-software approach, though primarily focused on adult and sleep applications rather than neonatal seizure detection.
- ANT Neuro: ANT Neuro produces EEG hardware and software used in clinical and research neurophysiology. It is a direct comparable in EEG device manufacturing and is increasingly investing in AI-assisted EEG interpretation, though its positioning skews more toward research and adult neurology than neonatal ICU.
Broad incumbents
- Natus Medical: Natus is an established manufacturer of EEG, neurodiagnostic, and newborn care equipment used in NICUs worldwide. It competes with NeuroBell in neonatal EEG monitoring but as part of a much broader neurology and newborn-care portfolio rather than a focused AI seizure-detection niche.
- Nihon Kohden: Nihon Kohden is a global leader in patient monitoring and neurodiagnostic EEG systems used in ICUs. It overlaps with NeuroBell in NICU brain monitoring but competes as a full-line patient monitoring incumbent, not a neonatal-specific AI specialist.
- Masimo: Masimo is a major patient-monitoring company with brain-monitoring and ICU sedation-depth products. Its hospital salesforce, ICU footprint, and SedLine/Patient SafetyNet offerings position it as a broad incumbent that NeuroBell could displace or partner with in NICU settings.
- Medtronic: Medtronic is a diversified medical device leader with neurology and patient-monitoring businesses. It is relevant as a broad incumbent that competes for ICU capital budgets and could potentially acquire NeuroBell or partner to extend EEG/AI capabilities into its NICU offering.
Emerging players
- Empatica: Empatica builds wearable devices with AI-based seizure detection algorithms. It targets similar AI/seizure-detection capabilities as NeuroBell but via consumer wearables rather than NICU-grade clinical EEG, making it an adjacent emerging player rather than a direct competitor.
- Wave Neuroscience: Wave Neuroscience (and similar emerging AI-EEG analytics firms) brings AI-driven EEG interpretation to neurology workflows. It is comparable to NeuroBell's machine-learning seizure detection layer but generally serves outpatient and research neurology rather than acute neonatal care.
- iCE Neurosystems: iCE Neurosystems provides continuous EEG monitoring and AI analytics for hospital ICUs. It targets a closely overlapping use case (continuous ICU brain monitoring with decision support) and is an emerging-play alternative path to the same clinical problem NeuroBell addresses.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Neurobell social profiles
Digital presenceNeurobell compliance and trust
Trust signalCompliance1 record
Neurobell financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neurobell leadership team
Management profileNumber of profiles
Profiles5 records
Neurobell funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neurobell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neurobell
What does Neurobell do?
NeuroBell develops Luna, a portable, pocket-sized, wireless 8-channel EEG monitor with AI-powered automated seizure detection for use in neonatal ICUs. The device is battery-powered, WiFi-enabled, compliant with ACNS and 10-20 EEG placement for neonates, and features a two-button setup process for NICU staff. It integrates deep-learning automated seizure detection with cloud-based EEG data review and storage, providing bedside decision support.
Is Neurobell a public or private company?
Neurobell is a private company. It is classified as venture growth investor backed and is currently operating.
When was Neurobell founded?
Neurobell was founded in 2023. It employs 1 to 10 people.
Where is Neurobell based?
Neurobell is headquartered in Cork, Ireland, in the Europe region.
How does Neurobell make money?
One revenue line is on record: medical Device Sales (Luna).
Who are Neurobell's main competitors?
Direct peers on record are Ceribell, Compumedics and ANT Neuro. Broad incumbents are Natus Medical, Nihon Kohden, Masimo and Medtronic. Emerging players are Empatica, Wave Neuroscience and iCE Neurosystems.
Does Neurobell have an API?
No public API is recorded for Neurobell.
What industry is Neurobell in?
Neurobell's product category is Neonatal EEG Monitoring Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACAPAG, Maternal, Neonatal & Pediatric Remote Monitoring. Its NAICS code is 334510 and its SIC code is 3845.